베이진 (ONC) 주가

베이진(ONC)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $350.84 (-0.74%), 시가총액 $30.43B, PER (주가수익비율) 66.20, 52주 최저~최고 $233.37 ~ $377.47.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products com

핵심 지표

• 현재가: $350.84 (-0.74%)
• 시가총액: $30.43B
• PER (주가수익비율): 66.20
• 52주 최저~최고: $233.37 ~ $377.47
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

베이진의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.

베이진 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4.5833

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 6.80
• 순이익률: 0.09%
• 영업이익률: 0.17%

자주 묻는 질문